JP2023181410A - Composition for suppressing decline of mental function - Google Patents
Composition for suppressing decline of mental function Download PDFInfo
- Publication number
- JP2023181410A JP2023181410A JP2023187284A JP2023187284A JP2023181410A JP 2023181410 A JP2023181410 A JP 2023181410A JP 2023187284 A JP2023187284 A JP 2023187284A JP 2023187284 A JP2023187284 A JP 2023187284A JP 2023181410 A JP2023181410 A JP 2023181410A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- present
- mental function
- decline
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 230000003340 mental effect Effects 0.000 title claims abstract description 53
- 230000007423 decrease Effects 0.000 title claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 89
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 18
- 230000036506 anxiety Effects 0.000 claims abstract description 18
- 239000012453 solvate Substances 0.000 claims abstract description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims description 43
- 230000003247 decreasing effect Effects 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 abstract description 11
- 230000006870 function Effects 0.000 description 42
- 238000002360 preparation method Methods 0.000 description 31
- 238000012360 testing method Methods 0.000 description 15
- 244000269722 Thea sinensis Species 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 230000008450 motivation Effects 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 235000013616 tea Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 108010046377 Whey Proteins Proteins 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000007544 Whey Proteins Human genes 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 208000020401 Depressive disease Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000005862 Whey Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 235000021119 whey protein Nutrition 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- -1 inorganic acid salts Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 235000015192 vegetable juice Nutrition 0.000 description 4
- 238000001061 Dunnett's test Methods 0.000 description 3
- 235000013405 beer Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000008717 functional decline Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 235000015897 energy drink Nutrition 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000249058 Anthracothorax Species 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 240000006914 Aspalathus linearis Species 0.000 description 1
- 235000012984 Aspalathus linearis Nutrition 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000207620 Euterpe oleracea Species 0.000 description 1
- 235000012601 Euterpe oleracea Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000283203 Otariidae Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000003650 acai Nutrition 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007267 depressive like behavior Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 108010050792 glutenin Proteins 0.000 description 1
- 108010083391 glycinin Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000020330 rooibos tea Nutrition 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明は、精神機能の低下抑制等のための組成物に関する。 TECHNICAL FIELD The present invention relates to a composition for suppressing decline in mental function, etc.
現代社会においては若年層から老年層まで幅広い世代において疲労やストレス等により意欲の低下や抑うつ症状等の精神機能の低下がみられる。精神機能の低下は仕事の生産性の低下や日常生活の質の低下に直結することから大きな社会問題となっている。 In modern society, a decline in mental function, such as a decrease in motivation and depressive symptoms, is observed in a wide range of generations, from the young to the elderly, due to fatigue and stress. Decline in mental function has become a major social problem because it is directly linked to decreases in work productivity and quality of daily life.
これまでに精神機能の低下を改善する食品素材としてホエイタンパク質加水分解物が示唆されている（特許文献１）が、精神機能の低下抑制に有効な、日常生活において手軽に摂取できる食品素材は未だ少ないのが現状である。 Whey protein hydrolyzate has been suggested as a food material that can improve the decline in mental function (Patent Document 1), but there is still no food material that is effective in suppressing the decline in mental function and that can be easily ingested in daily life. The current situation is that there are few.
本発明は精神機能の低下を抑制することができる新規素材およびそれを含む組成物を提供することを目的とする。 An object of the present invention is to provide a new material capable of suppressing decline in mental function and a composition containing the same.
本発明者は今般、テトラペプチドＧＴＷＹが、尾懸垂試験において抑うつ状態および意欲低下を改善することを見出した。本発明はこの知見に基づくものである。 The inventors have now found that the tetrapeptide GTWY improves depression and decreased motivation in the tail suspension test. The present invention is based on this knowledge.
すなわち、本発明によれば以下の発明が提供される。
［１］ＧＴＷＹ（配列番号１）のアミノ酸配列を有するペプチドまたはその薬学上許容される塩もしくは溶媒和物を有効成分として含んでなる、精神機能の低下抑制用組成物および精神機能の低下抑制剤。
［２］精神機能の低下が、うつに関連する状態および不安に関連する状態からなる群から選択される１種または２種以上の状態である、上記［１］に記載の組成物および用剤。
［３］精神機能が低下した対象または精神機能の低下のリスクがある対象に摂取させる、上記［１］または［２］に記載の組成物および用剤。
［４］ＧＴＷＹ（配列番号１）のアミノ酸配列を有するペプチドまたはその薬学上許容される塩もしくは溶媒和物を、ヒト１日当たり０．０１～１００ｍｇ（乾燥質量換算）の量で対象に摂取させる、上記［１］～［３］のいずれかに記載の組成物および用剤。
［５］食品組成物である、上記［１］～［４］のいずれかに記載の組成物および用剤。
［６］１回摂取に適した単位包装形態である、上記［１］～［５］のいずれかに記載の組成物および用剤。
［７］ＧＴＷＹ（配列番号１）のアミノ酸配列を有するペプチドまたはその薬学上許容される塩もしくは溶媒和物を有効成分として含んでなる、うつおよび／または不安の治療、予防または改善用組成物およびうつおよび／または不安の治療、予防または改善剤。
That is, according to the present invention, the following inventions are provided.
[1] A composition for suppressing decline in mental function and an agent for suppressing decline in mental function, comprising a peptide having the amino acid sequence GTWY (SEQ ID NO: 1) or a pharmaceutically acceptable salt or solvate thereof as an active ingredient .
[2] The composition and preparation according to [1] above, wherein the decline in mental function is one or more conditions selected from the group consisting of depression-related conditions and anxiety-related conditions. .
[3] The composition and preparation described in [1] or [2] above, which are ingested by a subject with decreased mental function or a subject at risk of decreased mental function.
[4] A subject ingests a peptide having the amino acid sequence GTWY (SEQ ID NO: 1) or a pharmaceutically acceptable salt or solvate thereof in an amount of 0.01 to 100 mg (dry mass equivalent) per day for humans. The composition and preparation according to any one of [1] to [3] above.
[5] The composition and preparation according to any one of [1] to [4] above, which are food compositions.
[6] The composition and preparation according to any one of [1] to [5] above, which are in a unit packaging form suitable for one-time consumption.
[7] A composition for treating, preventing or improving depression and/or anxiety, comprising a peptide having the amino acid sequence of GTWY (SEQ ID NO: 1) or a pharmaceutically acceptable salt or solvate thereof as an active ingredient; Agents for treating, preventing or improving depression and/or anxiety.
上記［１］と上記［７］の組成物を本明細書において「本発明の組成物」と、上記［１］と上記［７］の用剤を本明細書において「本発明の用剤」と、それぞれいうことがある。 The compositions of [1] and [7] above are herein referred to as "compositions of the present invention", and the preparations of [1] and [7] above are herein referred to as "medications of the present invention". Each of them has something to say.
本発明の組成物および用剤が有効成分とするテトラペプチド：ＧＴＷＹ（配列番号１）は、精神機能の低下抑制機能を発揮する機能性素材として利用できるとともに、ヒトを含む哺乳類に安全な機能性素材として利用できる点で有利である。 The tetrapeptide GTWY (SEQ ID NO: 1), which is the active ingredient in the compositions and preparations of the present invention, can be used as a functional material that suppresses the decline in mental function, and has a functional property that is safe for mammals including humans. It is advantageous in that it can be used as a material.
本発明の組成物および用剤は、ＧＴＷＹ（配列番号１）のアミノ酸配列を有するペプチド（以下、「本発明のペプチド」ということがある）を有効成分として含有してなるものである。ここで、「アミノ酸配列を有するペプチド」とは、該アミノ酸配列により配列が特定されたペプチドを意味する。なお、本発明のペプチドは、β－ラクトリンと称されることもある（Nutrients 2019, 11, 348; doi:10.3390/nu11020348）。 The compositions and preparations of the present invention contain a peptide having the amino acid sequence of GTWY (SEQ ID NO: 1) (hereinafter sometimes referred to as "the peptide of the present invention") as an active ingredient. Here, the term "peptide having an amino acid sequence" means a peptide whose sequence is specified by the amino acid sequence. Note that the peptide of the present invention is sometimes referred to as β-lactin (Nutrients 2019, 11, 348; doi:10.3390/nu11020348).
本発明のペプチドは、化学合成によって得られたものを用いてもよく、乳、大豆、小麦、卵、畜肉、魚肉、魚介などに由来するタンパク質やポリペプチド原料等から化学的もしくは酵素的に分解して得られたものを用いてもよい。具体的には、例えば、本発明のペプチドの配列は、少なくとも、乳のホエイやカゼイン、牛血清アルブミン（ＢＳＡ）、大豆のグリシニン、小麦のグルテニン、卵黄のリボビテリン、卵白のオボアルブミン、オボトランスフェリン、リゾチウム、チキン蛋白のコラーゲンなどに含まれているから、これら食品もしくは食品素材を酸加水分解やプロテアーゼによる酵素処理または微生物発酵等に供して、上記ペプチドを生成させることができる。本発明の組成物および用剤としては上記食品もしくは食品素材の調製物をそのまま用いてもよいし、濃縮物として、あるいはスプレードライや凍結乾燥等により乾燥粉末として用いてもよい。また、必要に応じて不純物、塩、酵素等の除去など、任意の程度の精製を施して用いてもよい。 The peptide of the present invention may be obtained by chemical synthesis, and can be chemically or enzymatically decomposed from protein or polypeptide raw materials derived from milk, soybeans, wheat, eggs, livestock meat, fish meat, seafood, etc. You may use the one obtained by doing so. Specifically, for example, the sequence of the peptide of the present invention includes at least whey and casein from milk, bovine serum albumin (BSA), glycinin from soybean, glutenin from wheat, ribovitellin from egg yolk, ovalbumin from egg white, ovotransferrin, Since it is contained in lysotium, collagen of chicken protein, etc., the above-mentioned peptide can be produced by subjecting these foods or food materials to acid hydrolysis, enzymatic treatment with protease, microbial fermentation, etc. For the compositions and preparations of the present invention, preparations of the foods or food materials mentioned above may be used as they are, or may be used as concentrates, or as dry powders by spray drying, freeze drying, or the like. In addition, it may be used after being purified to any degree, such as by removing impurities, salts, enzymes, etc., as necessary.
本発明のペプチドを構成するアミノ酸は、Ｌ型のアミノ酸のみから構成されていてもよいし、Ｄ型のアミノ酸のみから構成されていてもよいし、あるいは両者が混在したペプチドのいずれであってもよい。また、天然に存在するアミノ酸のみから構成されていてもよいし、アミノ酸にリン酸化やグリコシル化等、任意の官能基が結合した修飾アミノ酸のみから構成されていてもよいし、あるいは両者が混在したペプチドのいずれであってもよい。また、ペプチドが２以上の不斉炭素を含む場合には、エナンチオマー、ジアステレオマー、あるいは両者が混在したペプチドのいずれであってもよい。 The amino acids constituting the peptide of the present invention may be composed only of L-type amino acids, only D-type amino acids, or a mixture of both. good. In addition, it may be composed only of naturally occurring amino acids, it may be composed only of modified amino acids in which an arbitrary functional group such as phosphorylation or glycosylation is attached to an amino acid, or it may be composed of a mixture of both. It may be any peptide. Furthermore, when the peptide contains two or more asymmetric carbon atoms, it may be an enantiomer, a diastereomer, or a peptide containing a mixture of both.
さらに、本発明のペプチドは、遊離塩の形態であっても、その薬学上許容される塩または溶媒和物の形態であってもよく、本発明の組成物および用剤はこれらのいずれか、あるいはこれら全部または一部の混合物を含むものである。薬学上許容される塩としては酸付加塩、金属塩、アンモニウム塩および有機アミン付加塩が挙げられる。薬学上許容される酸付加塩としては、塩酸塩、硫酸塩、リン酸塩等の無機酸塩、酢酸塩、マレイン酸塩、フマル酸塩、クエン酸塩、メタンスルホン酸塩等の有機酸塩等が挙げられる。また、薬学上許容される金属塩としては、ナトリウム塩、カリウム塩等のアルカリ金属塩、マグネシウム塩、カルシウム塩等のアルカリ土類金属塩、アルミニウム塩、亜鉛塩等が挙げられる。また、薬学上許容されるアンモニウム塩としては、アンモニウム、テトラメチルアンモニウム等の塩が挙げられる。また、薬学上許容される有機アミン付加塩としては、モルホリン、ピペリジン等の付加塩が挙げられる。 Furthermore, the peptide of the present invention may be in the form of a free salt, or a pharmaceutically acceptable salt or solvate thereof, and the compositions and preparations of the present invention may include any of these, Alternatively, it includes a mixture of all or part of these. Pharmaceutically acceptable salts include acid addition salts, metal salts, ammonium salts and organic amine addition salts. Pharmaceutically acceptable acid addition salts include inorganic acid salts such as hydrochloride, sulfate, and phosphate, and organic acid salts such as acetate, maleate, fumarate, citrate, and methanesulfonate. etc. Further, pharmaceutically acceptable metal salts include alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as magnesium salts and calcium salts, aluminum salts, zinc salts, and the like. Furthermore, pharmaceutically acceptable ammonium salts include salts such as ammonium and tetramethylammonium. Furthermore, examples of pharmaceutically acceptable organic amine addition salts include addition salts of morpholine, piperidine, and the like.
本発明の組成物および用剤は、本発明のペプチド単独で、あるいは本発明のペプチドを含む素材（例えば、食品原料）として提供することができる。本発明の組成物および用剤はまた、本発明のペプチドまたは本発明のペプチドを含む素材と、他の成分（例えば、食品原料、食品添加物、製剤添加物）とを混合して提供することもできる。本発明の組成物および用剤における本発明のペプチドの含有量は、その目的、用途、形態、剤型、症状、体重等に応じて任意に定めることができ、本発明はこれに限定されないが、その含有量としては、全体量に対して、０．００００１～５０質量％（固形分換算）の割合で含有させることができ、さらに好ましくは０．０００１～１０質量％（固形分換算）の割合で含有させることができる。本発明においては、本発明の用剤を本発明のペプチドからなるものとし、本発明の組成物を本発明のペプチドと他の成分とを含んでなるものとすることができる。 The compositions and preparations of the present invention can be provided as the peptide of the present invention alone or as a material (eg, food raw material) containing the peptide of the present invention. The compositions and preparations of the present invention may also be provided by mixing the peptide of the present invention or a material containing the peptide of the present invention with other components (e.g., food raw materials, food additives, pharmaceutical additives). You can also do it. The content of the peptide of the present invention in the compositions and preparations of the present invention can be arbitrarily determined depending on the purpose, use, form, dosage form, symptoms, body weight, etc., and the present invention is not limited thereto. The content thereof can be 0.00001 to 50% by mass (in terms of solid content), more preferably 0.0001 to 10% by mass (in terms of solid content) based on the total amount. It can be contained in a proportion. In the present invention, the preparation of the present invention may be composed of the peptide of the present invention, and the composition of the present invention may be composed of the peptide of the present invention and other components.
本発明のペプチドの含有量の測定は、液体クロマトグラフィータンデム質量分析法（ＬＣ／ＭＳ／ＭＳ）により実施することができる。当業者であればその条件設定は容易に行うことができ、測定の際に標準ペプチドとしてＬＣ／ＭＳ／ＭＳ測定用の純度のものを使用することはいうまでもないが、例えば、ＳＩＧＭＡ ＡＬＤＲＩＣＨ社製ＡＱＵＡペプチドを使用することができる。 The content of the peptide of the present invention can be measured by liquid chromatography tandem mass spectrometry (LC/MS/MS). Those skilled in the art can easily set the conditions, and it goes without saying that standard peptides of purity suitable for LC/MS/MS measurements are used during measurements; AQUA peptide manufactured by AQUA can be used.
本発明のペプチドを含む食品素材としては、タンパク質の酵素分解物が挙げられ、好ましくはホエイタンパク質の酵素分解物（以下、「ホエイ分解物」ということがある）である。本発明のペプチドが含まれるホエイ分解物の製造方法は公知であり、例えば、国際公開公報第２０１７／０８６３０３号の記載に従って製造することができる。あるいは、本発明のペプチドを含有する市販のホエイ酵素分解物を用いてもよく、例えば、ＬＥ８０ＧＦ－ＵＳ（ＤＭＶ社製）やＨＷ－３（雪印メグミルク社製）を本発明のペプチドとして用いてもよい。 Food materials containing the peptide of the present invention include enzymatic decomposition products of proteins, preferably enzymatic decomposition products of whey proteins (hereinafter sometimes referred to as "whey decomposition products"). A method for producing a whey decomposition product containing the peptide of the present invention is known, and can be produced, for example, according to the description in International Publication No. 2017/086303. Alternatively, a commercially available whey enzymatic decomposition product containing the peptide of the present invention may be used; for example, LE80GF-US (manufactured by DMV) or HW-3 (manufactured by Megmilk Snow Brand) may be used as the peptide of the present invention. good.
本発明のペプチドをホエイタンパク質分解物として本発明の組成物および用剤に含有させる場合、本発明のペプチドをホエイタンパク質分解物に対して、０．００１～１０質量％（固形分換算）の割合で含有させることができ、さらに好ましくは０．０１～５質量％（固形分換算）の割合で含有させることができる。また、本発明の組成物および用剤に対して、ホエイタンパク質分解物は、０．００１～９５質量％（固形分換算）の割合で含有させることができ、好ましくは０．０１～５０質量％（固形分換算）の割合で含有させることができる。 When the peptide of the present invention is contained in the compositions and preparations of the present invention as a whey protein decomposition product, the peptide of the present invention is contained in a proportion of 0.001 to 10% by mass (solid content equivalent) based on the whey protein decomposition product. It can be contained in an amount of 0.01 to 5% by mass (based on solid content), and more preferably in an amount of 0.01 to 5% by mass (based on solid content). Further, the whey protein decomposition product can be contained in the compositions and preparations of the present invention in a proportion of 0.001 to 95% by mass (in terms of solid content), preferably 0.01 to 50% by mass. (in terms of solid content).
後記実施例に示されるように、本発明のペプチドは、抑うつ状態および意欲低下の改善作用を有する。抑うつ状態や意欲低下は精神機能の低下の代表例であることから、本発明のペプチドは精神機能の低下抑制用組成物および精神機能低下抑制剤の有効成分として使用することができる。 As shown in the Examples below, the peptide of the present invention has an ameliorating effect on depressive state and loss of motivation. Since a depressed state and a decrease in motivation are typical examples of a decrease in mental function, the peptide of the present invention can be used as an active ingredient in a composition for suppressing a decrease in mental function and an agent for suppressing a decrease in mental function.
本発明において「精神機能」は、情意機能（感情や意志の機能）および精神活力を含む意味で用いられる。「精神機能の低下」の例としては、うつに関連する状態および不安に関連する状態が挙げられる。うつに関連する状態としては、例えば、抑うつ状態、意欲低下、モチベーション低下、気力低下、活力低下、悲壮感、孤独感、落ち込み、絶望感、好奇心低下が挙げられる。不安に関連する状態としては、例えば、不安感、精神的疲労感、心細い感じ、落ち着かない気持ち、うろたえ、恐怖感、あれこれ心配な感じが挙げられる。 In the present invention, "mental function" is used to include emotional function (emotional and volitional functions) and mental vitality. Examples of "decreased mental function" include conditions associated with depression and conditions associated with anxiety. Conditions related to depression include, for example, a depressed state, decreased desire, decreased motivation, decreased energy, decreased vitality, feeling of sadness, feeling of loneliness, depression, feeling of hopelessness, and decreased curiosity. Conditions related to anxiety include, for example, a feeling of anxiety, a feeling of mental fatigue, a feeling of anxiety, a feeling of restlessness, a feeling of confusion, a feeling of fear, and a feeling of worrying about various things.
本発明において「精神機能の低下抑制」は、精神機能が低下した対象において精神機能を改善することのみならず、精神機能の低下のリスクがある対象において該リスクを低減することを含む意味で用いられる。すなわち、本発明の組成物および用剤は、精神機能が低下した対象または精神機能の低下のリスクがある対象に摂取させるか、あるいは投与することができる。ここで、「精神機能の低下のリスクがある対象」は、精神機能が低下していないが、将来において精神機能の低下の恐れがある対象を意味する。また、「リスクの低減」は、精神機能の低下を緩和することを含む。なお、摂取または投与対象は後述のようにヒトを含む哺乳動物である。 In the present invention, "suppressing decline in mental function" is used to include not only improving mental function in a subject with a decline in mental function, but also reducing the risk of decline in mental function in a subject who is at risk of decline in mental function. It will be done. That is, the compositions and preparations of the present invention can be ingested or administered to subjects with decreased mental function or subjects at risk of decreased mental function. Here, the term "subject at risk of decline in mental function" means a subject whose mental function has not declined, but who is at risk of decline in mental function in the future. Furthermore, "reducing risk" includes alleviating decline in mental function. The subjects to be ingested or administered are mammals including humans, as described below.
上記のように、本発明のペプチドは精神機能の低下の抑制に使用することができる。精神機能の低下は抑うつ状態や不安状態の発症および進展に関与していることから、本発明のペプチドはうつおよび不安の治療、予防または改善用組成物およびうつおよび不安の治療、予防または改善剤の有効成分として使用することができる。すなわち、本発明によれば、本発明のペプチドを含んでなる、うつおよび／または不安の治療、予防または改善用組成物と、本発明のペプチドを含んでなる、うつおよび／または不安の治療、予防または改善剤が提供される。 As mentioned above, the peptides of the present invention can be used to suppress decline in mental function. Since a decline in mental function is involved in the onset and progression of depression and anxiety, the peptide of the present invention can be used as a composition for treating, preventing or improving depression and anxiety, and as an agent for treating, preventing or improving depression and anxiety. It can be used as an active ingredient. That is, according to the present invention, a composition for treating, preventing or improving depression and/or anxiety comprising the peptide of the present invention, and a composition for treating depression and/or anxiety comprising the peptide of the present invention. A prophylactic or ameliorative agent is provided.
本発明の組成物および用剤は、医薬品（例えば、医薬組成物）、医薬部外品、食品（例えば、食品組成物）、飼料（ペットフード含む）等の形態で提供することができ、下記の記載に従って実施することができる。 The compositions and preparations of the present invention can be provided in the form of pharmaceuticals (e.g., pharmaceutical compositions), quasi-drugs, foods (e.g., food compositions), feeds (including pet foods), etc. It can be carried out according to the description.
本発明のペプチドは、ヒトおよび非ヒト動物に経口投与することができる。経口剤としては、顆粒剤、散剤、錠剤（糖衣錠を含む）、丸剤、カプセル剤、シロップ剤、乳剤、懸濁剤が挙げられる。これらの製剤は、当分野で通常行われている手法により、薬学上許容される担体を用いて製剤化することができる。薬学上許容される担体としては、賦形剤、結合剤、希釈剤、添加剤、香料、緩衝剤、増粘剤、着色剤、安定剤、乳化剤、分散剤、懸濁化剤、防腐剤等が挙げられる。 The peptides of the invention can be orally administered to humans and non-human animals. Oral preparations include granules, powders, tablets (including sugar-coated tablets), pills, capsules, syrups, emulsions, and suspensions. These preparations can be formulated using pharmaceutically acceptable carriers by methods commonly practiced in the art. Pharmaceutically acceptable carriers include excipients, binders, diluents, additives, fragrances, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc. can be mentioned.
本発明のペプチドを食品として提供する場合には、それをそのまま食品として提供することができ、あるいはそれを食品に含有させて提供することができる。例えば、本発明のペプチドを食品として提供する場合には、本発明のペプチドを含有する、ホエイ分解物等のタンパク質の酵素分解物等を、そのまま食品として提供することができ、あるいはそれを食品に含有させて提供することができる。このようにして提供された食品は本発明のペプチドを有効量含有した食品である。本明細書において、本発明のペプチドを「有効量含有した」とは、個々の食品において通常喫食される量を摂取した場合に後述するような範囲で本発明のペプチドが摂取されるような含有量をいう。また「食品」とは、健康食品、機能性食品、栄養補助食品、保健機能食品（例えば、特定保健用食品、栄養機能食品、機能性表示食品）、特別用途食品（例えば、幼児用食品、妊産婦用食品、病者用食品）およびサプリメントを含む意味で用いられる。なお、本発明のペプチドをヒト以外の動物に摂取させる場合には、本発明でいう食品が飼料として使用されることはいうまでもない。 When the peptide of the present invention is provided as a food, it can be provided as a food as it is, or it can be provided as a food. For example, when providing the peptide of the present invention as a food, an enzymatic decomposition product of protein such as a whey decomposition product containing the peptide of the present invention can be provided as a food as is, or it can be made into a food. It can be provided by containing. The food thus provided is a food containing an effective amount of the peptide of the present invention. As used herein, "containing an effective amount of the peptide of the present invention" means that the peptide of the present invention is contained in an amount such that the peptide of the present invention is ingested within the range described below when the amount normally consumed in an individual food is ingested. Refers to quantity. In addition, "food" refers to health foods, functional foods, nutritional supplements, foods with health claims (e.g., foods for specified health uses, foods with nutritional function claims, foods with functional claims), foods for special purposes (e.g., foods for infants, Food for the sick, food for the sick) and supplements. It goes without saying that when the peptide of the present invention is ingested by animals other than humans, the food referred to in the present invention is used as feed.
本発明のペプチドは、上記のような精神機能の低下抑制効果を有するため、日常摂取する食品に含有させることができ、あるいは、サプリメントとして提供することができる。すなわち、本発明の組成物および用剤は食品の形態で提供することができる。この場合、本発明の組成物および用剤は１食当たりに摂取する量が予め定められた単位包装形態で提供することができる。１食当たりの単位包装形態としては、例えば、パック、包装、缶、ボトル等で一定量を規定する形態が挙げられる。本発明の組成物および用剤の各種作用をよりよく発揮させるためには、後述する、本発明のペプチドの１回当たりの摂取量に従って１食当たりの摂取量を決定できる。本発明の食品は、摂取量に関する説明事項が包装に表示されるか、あるいは説明事項が記載された文書等と一緒に提供されてもよい。 Since the peptide of the present invention has the effect of suppressing the decline in mental function as described above, it can be included in foods that are ingested on a daily basis, or it can be provided as a supplement. That is, the compositions and preparations of the present invention can be provided in the form of foods. In this case, the compositions and preparations of the present invention can be provided in a unit packaging form in which the amount to be ingested per meal is predetermined. Examples of unit packaging formats for one meal include formats that specify a certain amount in packs, packages, cans, bottles, and the like. In order to better exhibit the various effects of the compositions and preparations of the present invention, the intake amount per meal can be determined according to the intake amount of the peptide of the present invention per serving, which will be described later. The food of the present invention may have explanatory information regarding the intake amount displayed on the package, or may be provided together with a document containing explanatory information.
単位包装形態においてあらかじめ定められた１食当たりの摂取量は、１日当たりの有効摂取量であっても、１日当たりの有効摂取量を２回またはそれ以上（好ましくは２または３回）に分けた摂取量であってもよい。従って、本発明の組成物および用剤の単位包装形態には、後述のヒト１日当たりの摂取量で本発明のペプチドを含有させることができ、あるいは、後述のヒト１日当たりの摂取量の２分の１から６分の１の量で本発明のペプチドを含有させることができる。本発明の組成物および用剤は、摂取の便宜上、１食当たりの摂取量が１日当たりの有効摂取量である、「１食当たりの単位包装形態」で提供することが好ましい。 Even if the intake per meal predetermined in the unit package form is the effective intake per day, the effective intake per day is divided into two or more (preferably two or three) doses. It may be the intake amount. Therefore, the unit packaging form of the compositions and preparations of the present invention can contain the peptide of the present invention at the daily human intake amount described below, or 2 times the human daily intake amount described below. The peptide of the present invention can be contained in an amount of 1 to 1/6 of that amount. For convenience of ingestion, the compositions and preparations of the present invention are preferably provided in the form of "unit packaging per meal" in which the intake per meal is the effective daily intake.
「食品」の形態は特に限定されるものではなく、例えば、飲料の形態であっても、半液体やゲル状の形態であっても、固形体や粉末状の形態であってもよい。また、「サプリメント」としては、本発明のペプチドに賦形剤、結合剤等を加え練り合わせた後に打錠することにより製造された錠剤や、カプセル等に封入されたカプセル剤が挙げられる。 The form of the "food" is not particularly limited, and may be, for example, a drink, a semi-liquid or gel form, a solid or a powder form. Examples of "supplements" include tablets manufactured by adding excipients, binders, etc. to the peptide of the present invention, kneading the mixture, and then compressing the mixture, and capsules sealed in capsules.
本発明で提供される食品は、本発明のペプチドを含有する限り、特に限定されるものではないが、例えば、清涼飲料水、炭酸飲料、果汁入り飲料、野菜汁入り飲料、果汁および野菜汁入り飲料、牛乳等の畜乳、豆乳、乳飲料、ドリンクタイプのヨーグルト、ドリンクタイプやスティックタイプのゼリー、コーヒー、ココア、茶飲料、栄養ドリンク、エナジー飲料、スポーツドリンク、ミネラルウォーター、ニア・ウォーター、ノンアルコールのビールテイスト飲料等の非アルコール飲料；飯類、麺類、パン類およびパスタ類等炭水化物含有飲食品；チーズ類、ハードタイプまたはソフトタイプのヨーグルト、畜乳その他の油脂原料による生クリーム、アイスクリーム等の乳製品；クッキー、ケーキ、チョコレート等の洋菓子類、饅頭や羊羹等の和菓子類、ラムネ等のタブレット菓子（清涼菓子）、キャンディー類、ガム類、ゼリーやプリン等の冷菓や氷菓、スナック菓子等の各種菓子類；ウイスキー、バーボン、スピリッツ、リキュール、ワイン、果実酒、日本酒、中国酒、焼酎、ビール、アルコール度数１％以下のノンアルコールビール、発泡酒、その他雑酒、酎ハイ等のアルコール飲料；卵を用いた加工品、魚介類や畜肉（レバー等の臓物を含む）の加工品（珍味を含む）、味噌汁等のスープ類等の加工食品、みそ、しょうゆ、ふりかけ、その他シーズニング調味料等の調味料、濃厚流動食等の流動食等を例示することができる。なお、ミネラルウォーターは、発泡性および非発泡性のミネラルウォーターのいずれもが包含される。また、本発明で提供される食品には、食品製造原料および食品添加物のいずれもが含まれる。 The foods provided by the present invention are not particularly limited as long as they contain the peptide of the present invention, but include, for example, soft drinks, carbonated drinks, fruit juice-containing drinks, vegetable juice-containing drinks, fruit juices, and vegetable juice-containing drinks. Beverages, animal milk such as milk, soy milk, milk drinks, drink-type yogurt, drink-type and stick-type jelly, coffee, cocoa, tea drinks, energy drinks, energy drinks, sports drinks, mineral water, near water, non-alcoholic beverages Non-alcoholic beverages such as alcoholic beer-taste beverages; Carbohydrate-containing foods and beverages such as rice, noodles, bread, and pasta; Cheese, hard or soft yogurt, fresh cream and ice cream made from livestock milk and other fat and oil ingredients Dairy products such as cookies, cakes, chocolates, and other Western sweets; Japanese sweets such as manju and yokan; tablet sweets (refreshing sweets) such as ramune; candies; gum; frozen sweets such as jelly and pudding; snacks; etc. various confectioneries; whiskey, bourbon, spirits, liqueurs, wine, fruit liquor, Japanese sake, Chinese liquor, shochu, beer, non-alcoholic beer with an alcohol content of 1% or less, low-malt beer, other miscellaneous liquors, alcoholic beverages such as chuhai. Processed products using eggs, processed products (including delicacies) of seafood and meat (including offal such as liver), processed foods such as soups such as miso soup, miso, soy sauce, furikake, other seasonings, etc. Examples include seasonings, liquid foods such as concentrated liquid foods, and the like. Note that mineral water includes both sparkling and non-sparkling mineral water. Furthermore, the food provided by the present invention includes both food manufacturing raw materials and food additives.
茶飲料としては、発酵茶、半発酵茶および不発酵茶のいずれもが包含され、例えば、紅茶、緑茶、麦茶、玄米茶、煎茶、玉露茶、ほうじ茶、ウーロン茶、ウコン茶、プーアル茶、ルイボスティー、ローズ茶、キク茶、イチョウ葉茶、ハーブ茶（例えば、ミント茶、ジャスミン茶）が挙げられる。 Tea beverages include fermented tea, semi-fermented tea, and unfermented tea, such as black tea, green tea, barley tea, genmaicha, sencha, gyokuro tea, hojicha, oolong tea, turmeric tea, puerh tea, and rooibos tea. , rose tea, chrysanthemum tea, ginkgo leaf tea, and herbal tea (eg, mint tea, jasmine tea).
果汁入り飲料や果汁および野菜汁入り飲料に用いられる果物としては、例えば、リンゴ、ミカン、ブドウ、バナナ、ナシ、モモ、マンゴー、アサイー、ブルーベリーおよびウメが挙げられる。また、野菜汁入り飲料や果汁および野菜汁入り飲料に用いられる野菜としては、例えば、トマト、ニンジン、セロリ、カボチャ、キュウリおよびスイカが挙げられる。 Examples of fruits used in fruit juice-containing beverages and fruit and vegetable juice-containing beverages include apples, tangerines, grapes, bananas, pears, peaches, mangos, acai, blueberries, and plums. Further, examples of vegetables used in vegetable juice-containing beverages, fruit juices, and vegetable juice-containing beverages include tomatoes, carrots, celery, pumpkins, cucumbers, and watermelons.
本発明のペプチドの摂取量は、受容者の性別、年齢および体重、症状、投与時間、剤形、投与経路並びに組み合わせる薬剤等に依存して決定できる。精神機能の低下抑制を目的とした本発明のペプチドの成人１日当たりの摂取量（乾燥質量換算）は、例えば、０．０１～１００ｍｇ（好ましくは０．１～１０ｍｇ）である。上記の本発明のペプチドの摂取量および下記摂取タイミングおよび摂取期間は、本発明のペプチドを非治療目的および治療目的のいずれで使用する場合にも適用があり、治療目的の場合には摂取は投与に読み替えることができる。なお、本発明のペプチドはヒト以外の哺乳動物（例えば、マウス、ラット、ウサギ、イヌ、ネコ、ウシ、ウマ、ブタ、サル、イルカ、アシカ等）に対しても摂取させることができ、摂取量、摂取タイミングおよび摂取期間はヒトに関する記載を参考にして決定することができる。 The amount of the peptide of the present invention to be ingested can be determined depending on the recipient's gender, age and weight, symptoms, administration time, dosage form, administration route, combined drugs, and the like. The daily intake amount (in terms of dry mass) of the peptide of the present invention for the purpose of suppressing decline in mental function for an adult is, for example, 0.01 to 100 mg (preferably 0.1 to 10 mg). The above intake amount of the peptide of the present invention and the following intake timing and intake period are applicable to both non-therapeutic and therapeutic use of the peptide of the present invention; It can be read as . The peptide of the present invention can also be ingested by mammals other than humans (e.g., mice, rats, rabbits, dogs, cats, cows, horses, pigs, monkeys, dolphins, sea lions, etc.), and the intake amount The timing and duration of intake can be determined with reference to the descriptions regarding humans.
本発明の本発明のペプチドは、精神機能の低下抑制作用を期待する期間内は摂取を継続することが好ましい。すなわち、本発明のペプチドは、上記量での摂取または投与を少なくとも１日（好ましくは３日、より好ましくは５日、特に好ましくは１０日）間とすることができ、また、上記量での摂取または投与を１日１回（好ましくは、１日２回または１日３回）とすることができる。本発明のペプチドはまた、精神機能の低下抑制作用を期待する日時よりも前に摂取を開始することが望ましいため、その開始時期は上記期待時の当日（好ましくは当日１時間前）でもよく、上記期待日の１日前（好ましくは３日前、より好ましくは５日前）とすることができる。精神機能の低下抑制作用を期待する日時よりも前の例としては、精神機能の低下の原因となりうるストレスや疲労の前が挙げられる。 It is preferable that the ingestion of the peptide of the present invention is continued during the period in which the inhibitory effect on mental function decline is expected. That is, the peptide of the present invention can be ingested or administered in the above amount for at least 1 day (preferably 3 days, more preferably 5 days, particularly preferably 10 days); Ingestion or administration can be once a day (preferably twice a day or three times a day). It is also preferable to start taking the peptide of the present invention before the expected date and time for its effect on suppressing decline in mental function, so the start time may be on the same day (preferably 1 hour before that day) at the expected time. This can be done one day before the expected date (preferably three days before, more preferably five days before). An example of a time before the expected date and time to suppress the decline in mental function is before stress or fatigue that can cause a decline in mental function.
本発明の組成物および用剤並びに食品には、精神機能の低下抑制効果を有する旨の表示が付されてもよい。この場合、消費者に理解しやすい表示とするため本発明の組成物および用剤並びに食品には以下の一部または全部の表示が付されてもよい。なお、本発明において「精神機能の低下抑制」が以下の表示を含む意味で用いられることはいうまでもない。
・いろいろなことが心配な方に
・やる気が落ちやすい方に
・意欲、モチベーションまたは気力の低下が気になる方に
・落ち込みやすい方に
・前向きでいたい方に
・いらいらすると不安になってしまう方に
・緊張すると不安になってしまう方に
・プレッシャーがあると不安になってしまう方に
The compositions, preparations, and foods of the present invention may be labeled to the effect that they have the effect of suppressing decline in mental function. In this case, some or all of the following labels may be attached to the compositions, preparations, and foods of the present invention in order to make the labels easy for consumers to understand. It goes without saying that in the present invention, "suppression of decline in mental function" is used to include the following expressions.
- For those who are worried about various things - For those who tend to lose motivation - For those who are concerned about a decline in motivation, motivation, or energy - For those who are easily depressed - For those who want to stay positive - For those who become anxious when irritated・For those who become anxious when they are nervous ・For those who become anxious when under pressure
本発明の別の面によれば、有効量の本発明のペプチドまたはその薬学上許容される塩もしくは溶媒和物あるいはそれを含む組成物を、それを必要としている対象に摂取させるか、あるいは投与することを含んでなる、精神機能の低下抑制方法が提供される。本発明によればまた、有効量の本発明のペプチドまたはその薬学上許容される塩もしくは溶媒和物あるいはそれを含む組成物を、それを必要としている対象に摂取させるか、あるいは投与することを含んでなる、うつおよび／または不安の治療、予防または改善方法が提供される。本発明の方法は、本発明の組成物および用剤に関する記載に従って実施することができる。 According to another aspect of the invention, an effective amount of a peptide of the invention or a pharmaceutically acceptable salt or solvate thereof, or a composition comprising the same, is ingested or administered to a subject in need thereof. Provided is a method for suppressing decline in mental function, which comprises: The present invention also provides for ingesting or administering an effective amount of the peptide of the present invention, a pharmaceutically acceptable salt or solvate thereof, or a composition containing the same to a subject in need thereof. Provided are methods for treating, preventing or ameliorating depression and/or anxiety. The method of the invention can be carried out in accordance with the description regarding the compositions and preparations of the invention.
本発明のさらに別の面によれば、精神機能の低下抑制剤の製造のための、精神機能の低下抑制剤としての、あるいは本発明の方法における、本発明のペプチドまたはその薬学上許容される塩もしくは溶媒和物の使用が提供される。本発明の別の面によればまた、うつおよび／または不安の治療、予防または改善剤の製造のための、うつおよび／または不安の治療、予防または改善剤としての、あるいは本発明の方法における、本発明のペプチドまたはその薬学上許容される塩もしくは溶媒和物の使用が提供される。本発明の使用は、本発明の組成物および用剤に関する記載に従って実施することができる。 According to yet another aspect of the present invention, the peptide of the present invention or its pharmaceutically acceptable peptide as a mental function decline suppressant for the production of a mental function decline suppressant or in the method of the present invention. Use of salts or solvates is provided. According to another aspect of the invention, it also provides for the production of a treatment, prevention or amelioration agent for depression and/or anxiety, as a treatment, prevention or amelioration agent for depression and/or anxiety, or in the method of the invention. , uses of the peptides of the invention or pharmaceutically acceptable salts or solvates thereof are provided. The use of the invention can be carried out in accordance with the description regarding the compositions and preparations of the invention.
本発明のさらにまた別の面によれば、精神機能の低下抑制に用いるためのＧＴＷＹ（配列番号１）のアミノ酸配列を有するペプチドまたはその薬学上許容される塩もしくは溶媒和物が提供される。本発明によればまた、うつおよび／または不安の治療、予防または改善に用いるためのＧＴＷＹ（配列番号１）のアミノ酸配列を有するペプチドまたはその薬学上許容される塩もしくは溶媒和物が提供される。本発明によればまた、本発明の方法に用いるためのＧＴＷＹ（配列番号１）のアミノ酸配列を有するペプチドまたはその薬学上許容される塩もしくは溶媒和物が提供される。上記のＧＴＷＹ（配列番号１）のアミノ酸配列を有するペプチド並びにその薬学上許容される塩および溶媒和物は、本発明の組成物および用剤に関する記載に従って実施することができる。 According to still another aspect of the present invention, there is provided a peptide having the amino acid sequence of GTWY (SEQ ID NO: 1) or a pharmaceutically acceptable salt or solvate thereof for use in suppressing decline in mental function. According to the present invention, there is also provided a peptide having the amino acid sequence of GTWY (SEQ ID NO: 1) or a pharmaceutically acceptable salt or solvate thereof for use in treating, preventing or improving depression and/or anxiety. . The present invention also provides a peptide having the amino acid sequence of GTWY (SEQ ID NO: 1) or a pharmaceutically acceptable salt or solvate thereof for use in the method of the present invention. The above peptide having the amino acid sequence of GTWY (SEQ ID NO: 1) and its pharmaceutically acceptable salts and solvates can be prepared according to the description regarding the compositions and preparations of the present invention.
本発明の方法および本発明の使用はヒトを含む哺乳動物における使用であってもよく、治療的使用と非治療的使用のいずれもが意図される。本明細書において、「非治療的」とはヒトを手術、治療または診断する行為（すなわち、ヒトに対する医療行為）を含まないことを意味し、具体的には、医師または医師の指示を受けた者がヒトに対して手術、治療または診断を行う方法を含まないことを意味する。 The methods and uses of the invention may be used in mammals, including humans, and both therapeutic and non-therapeutic uses are contemplated. As used herein, "non-therapeutic" means that it does not include the act of surgery, treatment, or diagnosis of humans (i.e., medical treatment for humans), and specifically, it refers to the act of performing surgery, treatment, or diagnosis on humans (i.e., medical treatment for humans), and specifically, does not include methods by which a person performs surgery, treatment, or diagnosis on humans.
以下の例に基づき本発明をより具体的に説明するが、本発明はこれらの例に限定されるものではない。 The present invention will be explained in more detail based on the following examples, but the present invention is not limited to these examples.
実施例１：抑うつ状態および意欲低下に対するテトラペプチドの効果
（１）試験の概要
ＧＴＷＹペプチド（Ｂａｃｈｅｍ社）を蒸留水で溶解し、マウスへ経口投与１時間後に、尾懸垂試験を実施することにより抑うつおよび意欲・モチベーション低下に対する被験物質の改善効果を評価した。
Example 1: Effect of tetrapeptide on depressive state and loss of motivation (1) Overview of test GTWY peptide (Bachem) was dissolved in distilled water and 1 hour after oral administration to mice, depression was investigated by performing a tail suspension test. and the improvement effect of the test substance on motivation/motivation decline.
（２）ＧＴＷＹペプチドの投与
５週齢のＩＣＲ（ＣＤ－１）雄マウス（日本チャールズリバー社）を、１週間の馴化飼育の後、ＧＴＷＹペプチドを乾燥質量換算で０ｍｇ／ｋｇ体重、０．３ｍｇ／ｋｇ体重、１．０ｍｇ／ｋｇ体重となるように胃内へ強制経口投与した。投与したＧＴＷＹペプチドは、投与直前に蒸留水を添加することにより調製したものである。具体的には、投与する液量が１０ｍＬ／ｋｇ体重となるよう蒸留水で調製したＧＴＷＹペプチド水溶液を胃内へ強制経口投与した。また、０ｍｇ／ｋｇの群には、投与する液量が１０ｍＬ／ｋｇ体重となるように希釈溶媒（蒸留水）を胃内へ強制経口投与した。全て一群８匹で試験を実施した。
(2) Administration of GTWY peptide 5-week-old ICR (CD-1) male mice (Charles River Japan) were acclimatized for 1 week, and GTWY peptide was administered at 0 mg/kg body weight and 0.3 mg in terms of dry mass. The mice were forcibly administered orally into the stomach at a dose of 1.0 mg/kg body weight and 1.0 mg/kg body weight. The GTWY peptide administered was prepared by adding distilled water immediately before administration. Specifically, a GTWY peptide aqueous solution prepared with distilled water was forcibly administered into the stomach so that the amount of the administered liquid was 10 mL/kg body weight. In addition, to the 0 mg/kg group, a diluting solvent (distilled water) was forcibly administered orally into the stomach so that the amount of liquid administered was 10 mL/kg body weight. All tests were conducted with 8 animals per group.
（３）尾懸垂試験
上記（２）に記載のＧＴＷＹペプチドまたは蒸留水投与から１時間後に尾懸垂試験を実施した。具体的には、照度６０ルクス、温度２３．５±１℃の個別ケージ内で、逆さの状態のマウスの頭部がケージ底面から４５～５０ｃｍの高さになるように、ケージ上面にテープ（幅１ｃｍ、長さ１５ｃｍ）の一方の端を固定し、他方の端２ｃｍを、マウスの尾（尾の先端から１ｃｍの部位）に巻き付けてテープを尾に固定し、マウスを６分間吊るした（尾懸垂）。尾懸垂状態となったマウスをビデオカメラとモニタを用いて別室から目視し、６分間中の無動状態となった時間（無動時間）（秒）を測定した。なお、無動状態とは「マウスの四肢の動きが止まり、力み（りきみ）が無くなった状態」である。
(3) Tail suspension test A tail suspension test was conducted one hour after administration of the GTWY peptide or distilled water described in (2) above. Specifically, in an individual cage with an illuminance of 60 lux and a temperature of 23.5 ± 1°C, tape ( One end of the tape (
ここで、尾懸垂試験は抑うつ様行動を評価する方法として開発されたものである（Cryan JF, et al. Neurosci Biobehav Rev. 2005; 29: 571-625）。マウスの尾を固定し逆さの状態で吊すと、逃避行動の後に無動状態（動作を示さずぶら下がっている状態）が認められるため、一定時間中に認められる無動状態の発現時間を抑うつ様行動として評価する。尾懸垂試験で認められる無動状態は、実験動物が暴露された環境からの逃避を放棄した絶望状態、すなわち回避意欲の消失を意味するものと考えられており、意欲の指標ともなる。 Here, the tail suspension test was developed as a method for evaluating depressive-like behavior (Cryan JF, et al. Neurosci Biobehav Rev. 2005; 29: 571-625). When a mouse is hung upside down with its tail fixed, an immobile state (a state of hanging without any movement) is observed after the escape behavior, so the duration of the onset of the immobile state observed during a certain period of time is similar to that of depression. Evaluate as an action. The immobility observed in the tail suspension test is thought to represent a state of despair in which the experimental animal has given up on escaping from the exposed environment, that is, the loss of the desire to avoid, and is also an indicator of volition.
（５）結果
尾懸垂試験の結果は、図１および図２に示される通りであった。なお、検定は全て非投与群を対照としたダネットの検定によって行った。
(5) Results The results of the tail suspension test were as shown in FIGS. 1 and 2. All tests were performed by Dunnett's test using the non-administered group as a control.
図１に示される通り、尾懸垂試験の無動時間は、０．３ｍｇ／ｋｇおよび１．０ｍｇ／ｋｇＧＴＷＹペプチド投与群では、ＧＴＷＹペプチド非投与群と比較して、無動時間が有意に減少した。このことからＧＴＷＹペプチド投与によって、抑うつ状態および意欲低下が改善し、無動時間が減少したことが確認された。 As shown in Figure 1, the immobility time in the tail suspension test was significantly decreased in the 0.3 mg/kg and 1.0 mg/kg GTWY peptide administration groups compared to the GTWY peptide non-administration group. . This confirmed that administration of GTWY peptide improved the depressive state and decreased motivation, and reduced immobility time.
図２に示される通り、尾懸垂試験の無動時間は、０．１ｍｇ／ｋｇおよび０．３ｍｇ／ｋｇＧＴＷＹペプチド投与群では、非投与群と比較して、無動時間が有意に減少した。このことからＧＴＷＹペプチド投与によって、抑うつ状態および意欲低下が改善し、無動時間が減少したことが確認された。 As shown in FIG. 2, the immobility time in the tail suspension test was significantly reduced in the 0.1 mg/kg and 0.3 mg/kg GTWY peptide administration groups compared to the non-administration group. This confirmed that administration of GTWY peptide improved the depressive state and decreased motivation, and reduced immobility time.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023187284A JP2023181410A (en) | 2019-03-08 | 2023-10-31 | Composition for suppressing decline of mental function |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019042846A JP2020143035A (en) | 2019-03-08 | 2019-03-08 | Composition for suppressing decline of mental function |
| JP2023187284A JP2023181410A (en) | 2019-03-08 | 2023-10-31 | Composition for suppressing decline of mental function |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019042846A Division JP2020143035A (en) | 2019-03-08 | 2019-03-08 | Composition for suppressing decline of mental function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2023181410A true JP2023181410A (en) | 2023-12-21 |
Family
ID=72353211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019042846A Pending JP2020143035A (en) | 2019-03-08 | 2019-03-08 | Composition for suppressing decline of mental function |
| JP2023187284A Pending JP2023181410A (en) | 2019-03-08 | 2023-10-31 | Composition for suppressing decline of mental function |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019042846A Pending JP2020143035A (en) | 2019-03-08 | 2019-03-08 | Composition for suppressing decline of mental function |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP2020143035A (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1571925A1 (en) * | 2002-12-20 | 2005-09-14 | Unilever N.V. | Blood glucose regulating composition |
| CN108137650B (en) * | 2015-11-16 | 2022-04-08 | 麒麟控股株式会社 | Peptide composition and method for producing same |
-
2019
- 2019-03-08 JP JP2019042846A patent/JP2020143035A/en active Pending
-
2023
- 2023-10-31 JP JP2023187284A patent/JP2023181410A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020143035A (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7179908B2 (en) | PEPTIDE COMPOSITION AND METHOD FOR MANUFACTURE THEREOF | |
| RU2388485C2 (en) | Glucagon-like peptide-1 secretagogue, foodstuffs and beverages stimulating clucagon-like peptide 1 secretion, postprandial hyperglycemia inhibitor and foodstuffs and beverages inhibiting postprandial hyperglycemia | |
| US8921310B2 (en) | Method for accelerating mammalian body fat metabolism | |
| TWI784004B (en) | Use of acetic acid and/or acetate salts in the manufacture of compositions for improving brain function | |
| JP4395658B2 (en) | Composition for inhibiting cholesterol re-elevation and method of use thereof | |
| JP2023181410A (en) | Composition for suppressing decline of mental function | |
| JP7011984B2 (en) | Composition for improving attention function and judgment function | |
| JP4915959B2 (en) | Novel sweetener with sugar-like taste, production method and use thereof | |
| JP7231313B2 (en) | Composition for lowering blood pressure | |
| JP7313854B2 (en) | Composition for improving the appearance of hair | |
| JP7368949B2 (en) | Composition for suppressing increase in brain glutamic acid concentration | |
| JP7293556B2 (en) | Composition for suppressing decrease in muscle mass | |
| JP7139727B2 (en) | COMPOSITION FOR IMPROVING MOTOR CONTROL FUNCTION AND MOTOR LEARNING FUNCTION | |
| JP2009114112A (en) | Anti-osteoporosis agent | |
| JP7462338B2 (en) | Anti-fatigue | |
| JP2023107887A (en) | Composition for increasing cerebral blood flow | |
| JP2006063021A (en) | Hypotensive agent and food having hypotensive action | |
| US20050032710A1 (en) | Alternative agent with vitamin D-like activity and an improving agent for intestinal function | |
| KR101699123B1 (en) | Composition for decreasing corticosterone | |
| WO2019168149A1 (en) | Peptide capable of improving cognitive function | |
| JP2020158412A (en) | Cognitive function improving composition | |
| JP2022135015A (en) | opioid receptor agonist | |
| JP5943516B2 (en) | Sweetener for improving biological function comprising D-sorbose as an active ingredient | |
| TW201909891A (en) | Amino acid composition for promoting noradrenaline secretion | |
| JP2005104890A (en) | Composition for ameliorating orthosympathetic blood vessel abnormal contraction in climacterium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231127 |